- Visibility 433 Views
- Downloads 29 Downloads
- DOI 10.18231/j.ijooo.2021.029
-
CrossMark
- Citation
Sex hormones and dry eye disease: Current update
- Author Details:
-
Rajendra Prakash Maurya *
-
Ashish Gupta
-
Shivani Verma
-
Virendra P Singh
-
Anup Singh
-
Vibha Singh
-
Meghna Roy
-
Lokesh Mehla
-
Rahul Kumar
Introduction
According to international Dry Eye Workshop (DEWS) report in 2007, Dry eye disease (DED) is defined as a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.[1] It is one of the most common complaints in ophthalmic practice. Common symptoms of DED include foreign body sensation, grittiness, itching, burning, stinging, tearing, photophobia, fluctuating or blurry vision, leading to ocular discomfort and reduced visual acuity which significantly affects the quality of life of patients.[2], [3], [4], [5] Peri and post-menopausal women, elderly, contact lens wearers, those exposed to environmental and occupational factors, patients after refractive surgery, suffering from autoimmune diseases or under some topical or systemic therapies are more prone to dry eye disease.[6] The prevalence of DED ranges from 7.8% to 33.7%, depending on population being studied and assessment methods used.[7] A study in United States showed that the prevalence of DED in women over 50 years is 7% and in men over 50 years is 4%, nearly half of that in women.[8], [9] Other studies also showed that women has greater frequency and severity of DED than men, that’s why women’s well-being is much more affected by DED.[10] The frequency of DED increases with increasing age in both men and women and postmenopausal women are at higher risk of developing DED than younger women and men.[11]
Pathophysiology of Dry eye Disease
A preocular tear film is important for maintaining a smooth refractive corneal surface for optimal vision. [12], [13] Dry eye occurs when the tear film is disturbed as a result of decreased tear production or increased tear evaporation. [14] A normal tear film has three layers: inner hydrophilic mucin layer is mainly produced by conjunctival goblet cells and also by glycocalyx of the superficial layers of conjunctival and corneal epithelial cells, middle aqueous layer is produced by main and accessory lacrimal glands and outer lipid layer is secreted by meibomian glands (modified sebaceous glands). An integrated neural reflex loop (sensorimotor) balances aqueous production and tear evaporation thus maintaining normal tear film.[15] Ocular surface system (OSS) or lacrimal functional unit comprises of corneal epithelium, conjunctival epithelium with goblet cells, limbal stem cells that maintains epithelial turnover, tear film that keeps ocular surface moist and lubricated, main and accessory lacrimal glands, meibomian glands, eyelids while blinking help in distribution of tear film over the cornea, nasolacrimal duct and sensorimotor nerves connecting all these structures. All the components of OSS work synergistically to maintain ocular surface homeostasis and function of OSS is regulated by nervous, endocrine, vascular and immune systems [16] thus disturbance to any part of OSS compromises the normal neural feedback leading to impaired tear film and loss of ocular surface homeostasis. [17], [18] Hyperosmolarity of the tear film, either due to impaired production or increased evaporation of tears, activates inflammatory cascades in the ocular surface tissues which impairs the neural feedback mechanism to the lacrimal gland thus hampering tear production and clearance. [19], [20] Some evidence suggests that dry eye is an immune-based inflammatory disease affecting the ocular surface and lacrimal glands. [21], [22], [23] Clinically, dry eye is confirmed by increased corneal and conjunctival staining, low tear film break up time (TBUT), low Schirmer’s test score and tear hyperosmolarity. [24]
DEWS classifies dry eye into two major categories
Evaporative tear deficiency - It is the major primary dry eye disease phenotype. Lipid layer, secreted by meibomian glands, prevents tear evaporation, decreases surface tension and delay TBUT, therefore it is important for stabilization of the tear film. Lipid layer abnormalities leads to more evaporation and increased osmolarity of the tear film. Hyperosmolarity of tear film initiates inflammatory cascades in the ocular surface tissues, nociceptors detect inflammation and send signals to lacrimal glands via autonomic motor signals. The collection of symptoms along with hyperosmolarity of tears, signs of ocular inflammation in a setting of normal or higher than normal rate of aqueous fluid production is defined as evaporative dry eye. It is more commonly seen in women of 45 years or older. [25], [26], [27], [28], [29], [30], [31], [32]
Aqueous tear deficiency -It is characterized by decreased volume of tear production by the lacrimal glands. Reduced tear flow leads to hyperosmolarity of tears which initiates inflammatory cascades in the ocular surface tissues. Reduced lacrimal gland secretion can be primary due to any lacrimal gland disease pathology or secondary due to any ocular surface inflammation, which impairs sensory and autonomic secretomotor signals to the lacrimal gland leading to reduced secretion. Lacrimal gland atrophy, seen with CT scan, is age related in both men and women. [29], [33], [34]
Mucin layer helps in maintaining moisture in the eye, aqueous layer maintains tear volume as it contains water, electrolytes and protein and lipid layer aids in stabilization of the tear film as it prevents tear evaporation.
Dry eye affects women two to four times more than men and post-menopausal women are more prone to it. [9] Women with some systemic conditions like Sjogren’s syndrome, complete androgen insensitivity syndrome, premature ovarian failure, polycystic ovary syndrome (PCOS) and post-menopausal women using HRT have high prevalence of dry eye disease. [35], [36], [37], [38], [39], [40], [41], [42] Use of androgen antagonists for some prostate conditions in men is a sex specific risk factor for dry eye. [43], [44], [45] This shows that hormonal imbalance play an important role in the pathophysiology of dry eye disease, and gender and sex hormones may play a pivotal role in the etiology of dry eye.
Effects of gonadal hormones on Dry Eye -
Gonadal hormones and the Meibomian gland
Meibomian gland secretes lipid layer of the tear film, decreases surface tension and promotes stabilization of tear film by preventing evaporation of the underlying layer. Meibomian gland dysfunction leads to evaporative dry eye.[46] Sex hormones are known to regulate meibomian gland function.[45], [47], [48], [49] Androgens have positive impact on meibomian gland function and increases lipid secretion[48], [50] while estrogen and progesterone have a negative impact on meibomian gland function and thus decrease lipid secretion.[51], [52]
Effects of androgen on the meibomian gland
Meibomian gland is the target organ for androgen and is susceptible to effects of androgen. [53], [54] It also explicits mRNA for 5α-reductase enzyme which converts testosterone to its more potent form dihydrotestosterone (DHT).[55] Androgen stimulates expression of genes involved in lipid metabolic pathways and thus increases secretion of lipids from the meibomian gland, which forms the lipid layer of the tear film.[48], [54] Androgen also suppresses genes associated with keratinization of ductal epithelium, which is thought to be the probable cause of meibomian gland dysfunction, thus it enhances meibomian gland function.[52], [56] It's role in regulating the immune system in some studies shows that it imposes trophic effects on the lacrimal and meibomian gland function. [57] Thus androgen deficiency may lead to meibomian gland dysfunction, decreased quality and quantity of meibomian gland lipid layer leading to tear film instability, low tear film break-up time (TBUT) and subsequently evaporative dry eye. These changes are associated with gender and age, and are frequently seen in patients who are not responsive to androgen like women with complete androgen insensitivity syndrome and men with prostate cancer using androgen blockers. This shows the significance of androgen in the regulation of meibomian gland function.[38], [39], [43], [45], [58], [59], [60]
Genetically lower levels of androgen in women than men and age related decrease in gonadal androgen synthesis in both the sexes may lead to greater risk of dry eye in these populations. [59], [60], [61], [62], [63] In menopausal women, only 30% of the peak androgen level is found. [61], [64] The differences in meibomian gland lipid secretions between men and women may be due to differences in androgen levels between men and women. [59] With age, both sexes show structural and functional changes in the meibomian gland. Acinar cells atrophy and hyper keratinization of ductal epithelium causes more viscosity of the meibomian gland secretions leading to reduced gland function, increased tear film instability and dry eye. [65], [66], [58], [59], [67], [68], [69]
A study in orchiedctomized rabbits showed meibomian gland dysfunction due to androgen deficiency which got reversed on administering 19-nortestosterone. [48] Some studies showed that topical testosterone applied to the eyelids improve lipid layer thickness and TBUT and is used in men and women with meibomian gland dysfunction and evaporative dry eye [70], [71] The use of androgen precursor DHEA (Dehydroepiandrosterone) in dry eye patients stimulate the production and release of lipids from the meibomian glands and thus improves signs and symptoms of DED [70], [72] Surprisingly in Sjogren’s syndrome, DHEA couldn’t improve tear production and ocular surface pathology [73], [74] as according to many authors, intracrine conversion of DHEA to testosterone and DHT is suppressed in Sjogren’s syndrome. [75]
Effects of estrogen and progesterone on the meibomian gland
Estrogen and progesterone receptors are also present in meibomian gland and these hormones regulate the expression of several genes. The action of estrogen on meibomian gland is opposite to that of androgen. Estrogen inhibits lipid synthesis in meibomian gland and promotes meibomian gland dysfunction and thus causes evaporative dry eye.[52] This explains the increased prevalence of dry eye in postmenopausal women using hormone replacement therapy. As studies on mice-show that estrogen effects on sebaceous glands doesn’t occur directly through the interaction with their receptors but indirectly by antagonizing the effect of androgen on sebaceous glands, by blocking their uptake or conversion to more potent form DHT.[76], [77] Thus high prevalence of dry eye among women may not be due to increased action of estrogen but due to decreased action of the androgen in women. This also explains high prevalence of DED among post-menopausal women despite the cessation of estradiol synthesis in ovary. Testosterone upregulate the expression of genes involved in meibomian gland lipid synthesis while estrogen downregulate these genes and upregulate those genes which have the opposite effect [51], [52] Progesterone downregulates the expression of genes involved in immune eprocesses but its effect is much less than that of estrogen. [51] A study in mice shows that the sex-related differences in gene expression in the meibomian glands are mainly due to androgen and partly due to estrogen and progesterone.[78], [79] Aromatase inhibition in mice leading to estrogen deficiency has no effect on histology of meibomian glands.[79] Thus, the sex-related differences in biological processes, molecular functions and cellular components in the meibomian gland could be due to the effects of androgen rather than estrogen and progesterone. [80], [81], [78] More research is required to determine the definitive role of estrogen and progesterone on human meibomian gland and in evaporative dry eye.
Gonadal hormones and the lacrimal gland
Lacrimal gland's basic function is to synthesize and secrete water, proteins and electrolytes, which forms the aqueous layer of the tear film.[82], [83] Main and accessory lacrimal glands express genes for androgen and estrogen receptors and through regulation of the transcription of these genes, gonadal hormones control their structure and function.[83], [84], [85], [86] Androgens have a positive impact on lacrimal gland tissue and controls their morphology, cellular biology, biochemistry and secretory immune system, as shown in various animal studies, and is responsible for sex-related differences in the lacrimal gland.[87], [88] On the other hand, the role of estrogen and progesterone on lacrimal gland tissue is not very conclusive.[89], [90]
Effects of androgen on the Lacrimal gland
The lacrimal gland is also a target organ for androgens [84] and its structural, functional and pathological characteristics are regulated by androgens [91], [85], [87], [92] and these sex-related differences in androgen influence on lacrimal glands leads to sexual dimorphism in lacrimal gland characteristics, as seen in many animal studies. [91], [92], [93], [94], [95]
Lacrimal gland of male rabbit is larger in size than females. [96] Castration of male rats leads to decrease in size of lacrimal glands to that of female rats due to decrease in endogenous androgen. On treating castrated rats and female rats with DHT, there is a change in the characteristics of lacrimal gland to that of intact males. [87], [92] Androgen influences lacrimal gland function by increasing total DNA and protein in the gland and stimulating fluid secretion from the lacrimal gland. [88] Intact male rats synthesize and secrete more immunoglobulin A and glycoprotein from the acinar cells than female or castrated male rats. DHT treatment in castrated rats also stimulates the secretory immune system of the lacrimal gland [92], [93], [96], [97]
Primary lacrimal gland deficiency exists in women who have decreased androgen levels such as menopausal women or ovariectomized women or women using oral contraceptives, in spite of their variable estrogen levels. [98], [99], [100] In contrast, men on anti-androgen therapy don’t show changes in their lacrimal gland secretion. [101] This suggests that androgen may have sex-specific action. In autoimmune disease like Sjogren’s syndrome, which is characterized by inflammatory changes in the lacrimal gland leading to aqueous deficient dry eye, reduced levels of androgen have been found.[102], [37]
The sex-related differences in the effect of androgen on the lacrimal gland is partly due to variations in gene expression. [103], [85], [104], [105], [106], [107] In orchiectomized male and ovariectomized female rats, the number of binding sites and density of androgen receptor proteins are similar in the lacrimal gland [91] but in intact male rats, binding sites and androgen receptor proteins exists in far more numbers than in intact female rats. [84], [102] Androgen use in castrated rats restore the number of androgen receptors and binding sites to that in intact male rats, suggesting that androgens may autoregulate their own binding sites. [102], [108] Use of androgen antagonists or mutations in receptor proteins lead to decreased androgen action and inhibition of transcription and translation of genes. [92], [109], [110] These findings suggest that through alterations in gene activity, androgen action on the lacrimal gland can be regulated.[85]
Effect of estrogen and progesterone on the lacrimal gland
Effect of estrogen and progesterone on the lacrimal gland has contradictory results. Some human and animal studies suggests that they have proinflammatory role and stimulates autoimmune disease in the lacrimal gland, [111], [112] whereas other studies suggest anti-inflammatory role of these hormones on the lacrimal gland [88], [89], [90] and some studies didn’t find any effect of estrogen on the morphology and function of lacrimal gland. [93], [97], [113], [106], [114], [115], [116], [117], [95]
Recent studies show that in ovariectomized rats, there is decreased production and secretion, less TBUT and increased staining of ocular surface[117], [118] and administration of estrogen worsen the findings. [119] Estrogen and progesterone increases inflammation and autoimmune diseases in the lacrimal gland. One study in ovariectomized rabbits found that on estrogen treatment, there is an increase in the level of matrix metalloproteinases (MMPs) 2 and 9, a proteolytic enzyme involved in the regulation of inflammatory processes. [120]
Some studies suggested that dry eye in postmenopausal women may be due to decreased levels of estrogen and progesterone which causes increased production of proinflammatory cytokines, fibrosis and atrophy of the lacrimal gland.[121], [122] Studies in rabbit and mouse models with Sjogren’s syndrome shows that absence of estrogen causes inflammation and regressive changes in the lacrimal gland and estrogen administration causes reversal of these changes, inhibits lymphocyte infiltration and increases fluid production from the lacrimal gland. [123], [90], [112] Estrogen and progesterone influences expression of many immune-related genes and also upregulates the genes that inhibits signaling of pro-inflammatory cytokines.[86], [124] This shows that estrogen may have anti-inflammatory role in the lacrimal gland. Aromatase knockout in C57BL/6J mice suggests that estrogen has neither proinflammatory nor anti-inflammatory role.[125]
In lacrimal gland, estrogen and progesterone antagonize the expression of genes that are stimulated in response to androgen.[52] In comparison to androgen, estrogen and progesterone have very little role in the sex-related differences in gene expression and sexual dimorphism of the lacrimal gland, so the aqueous deficient dry eye in women may not be due to them.[103], [85], [96], [114], [86] More studies are required in humans to identify the role of estrogen and progesterone on the structure and function of the lacrimal gland and aqueous deficient dry eye.
Gonadal hormones and the ocular surface
Tissues of ocular surface, including cornea, conjunctiva and tear film are likely to be directly affected by gonadal hormones. Mucin layer is secreted mainly by conjunctival goblet cells and its main function is to stabilize the tear film and lubricate and protect the underlying ocular surface.[126], [127], [128] Any disturbance in mucin distribution over the ocular surface, due to change in goblet cell density, can lead to tear film instability and dry eye.[129], [130], [131], [132], [133], [134], [135]
Androgens have an effect on the conjunctival goblet cells and thus regulate mucin production.[135], [136] In women during menstruation, the cornea and conjunctiva are affected by physiological changes in the estrogen and progesterone concentrations.[137], [138], [139] Estrogen hase negative impact on cornea as high estrogen levels leads to decreased corneal sensitivity and thus leads to dry eye and inflammation of ocular surface. On the other hand, estrogen hase positive impact on the conjunctival epithelium as it enhances maturation of epithelial cells.[140]
Effects of androgen on the ocular surface
MUC5A is the secretory mucin which is produced by conjunctival goblet cells and MUCs 1,4 and 16 are membrane-associated mucins which are secreted by corneal and conjunctival epithelium and form the inner hydrophilic glycocalyx part of the mucous layer of tear film.[141], [142], [143], [144] Women with complete androgen insensitivity syndrome haves reduced levels of MUC5AC and MUC1 protein expression in the mucous layer of tear film, as a result of goblet cell dysfunction rather than decrease in goblet cell number.[136], [145]
Women with polycystic ovary syndrome (PCOS), despite having hyperandrogenism experience dry eye disease (DED).[42], [135] Hyperandrogenism in PCOS leads to goblet cell hyperplasia which leads to mucous hypersecretion but abnormal mucous filaments. These patients have increased MUC5A mRNA expression but reduced levels of MUC5A mucins in the conjunctival tissue and also have increased levels of MUC5AC in their tears, these findings can be attributed to abnormal mucous filaments on the ocular surface of PCOS patients.[135] Dry eye in PCOS has shorter TBUT and antiandrogen treatment has been demonstrated to increase TBUT and improves symptoms of dry eye but the side effects of prolonged systemic antiandrogen therapy should also be considered.
Effects of estrogen and progesterone on the ocular surface
Ocular surface tissues are susceptible to estrogen and progesterone levels. Hormonal changes during menstrual cycle, pregnancy, menopause, HRT and OCPs use in females have been linked to structural and functional changes in corneal and conjunctival epithelium, like decrease in corneal sensitivity and change in conjunctival maturation index and can also cause dry eye, affects visual function and leads to development of ocular symptoms.[139], [146], [147], [148], [149], [150], [151], [152], [153] These effects in cornea and conjunctiva are due to estrogen and/or progesterone, as testosterone levels remain relatively constant during the menstrual cycle.[137], [138], [139], [152]
Cornea express receptor for both estrogen and progesterone and these hormones probably reaches cornea from the tear film and aqueous humor. High estrogen levels cause reduced corneal sensitivity and this leads to impaired neural feedback to lacrimal gland for tear production and thus leads to dry eye.[149], [152] So, gonadal hormones have an indirect effect on the regulation of structure and function of cornea but their direct effect on cornea in dry eye is not known.
Conjunctival epithelium is sensitive to estrogen as the change in maturation index of its cells correlates with the changes in hormone levels during the menstrual cycle.[138] The relative levels of estrogen and progesterone in menstrual, follicular and luteal phase of the menstrual cycle correlate with relative proportions of immature parabasal, mature superficial and intermediate cells respectively.[137], [154], [140], [150] Post-menopause, these maturation changes in conjunctival epithelial cells are absent.[154], [140] and post-menopausal women have decreased number of goblet cells and are more susceptible to squamous metaplasia and inflammation.[129] On giving HRT in post-menopausal women, maturation of conjunctival cells occur and density of goblet cells increases, suggesting that estrogen have an influential effect on the maturation of conjunctival epithelial cells.[155], [156]
Some studies found that the other signs and symptoms of dry eye like tear turnover, volume, osmolarity and stability doesn’t change despite changes in estrogen and progesterone levels.[100], [157] Studies in human corneal epithelial cells also shows that treatment with estrogen upregulates both proinflammatory cytokines and MMPs in the cells, thus an inflammatory component is also present in response to estrogen, which could exacerbate DED.[158]
A study in ovariectomized mice shows that estrogen and progesterone exposure in ocular surface tissue didn’t affect the distribution and expression of mucin142. In contrast, a study in rabbits shows that estrogen exposure increases mucin secretion from the conjunctival goblet cells but increased progesterone has no effect on mucin secretion.[159] This shows the complexity in hormonal regulation of mucin.
Hormonal treatment in Dry eye
Ophthalmic examination in dry eye shows decreased tear production with increased tear film break up time (TBUT), increased tear osmolarity, increased corneal and conjunctival staining, low Schirmer’s test score in aqueous deficient dry eye and decreased levels of lactoferrin and lysozyme in tears.
First line of treatment in dry eye includes lubricating eye drops, second line includes anti-inflammatory drugs like steroid eye drops and immunomodulatory drugs like cyclosporine. In severe cases, punctual occlusion, eyelid corrective surgery, scleral contact lenses and autologous serum tears can be used, depending on the underlying cause.[160]
Many studies suggest that there might be an important role of hormonal therapy in dry eye treatment, specifically in menopausal women.
Role of HRT in dry eye
Role of HRT in dry eye treatment is inconclusive as some studies show exacerbation of symptoms whereas other studies show improvement of symptoms with HRT and some studies also show no effect of HRT on dry eye. A large population based study on post- menopausal women suggests that women receiving combined estrogen/progesterone HRT or only estrogen containing HRT developed more dry eye signs and symptoms as compared to women not receiving HRT with an odds ratio of 1.29 (prevalence of dry eye in estrogen alone HRT - 69% and estrogen plus progesterone HRT- 29%).[161], [162] This also shows that adding progesterone to HRT may have a protective effect in reducing dry eye symptoms.[162]
In some studies, it has been found that higher doses of HRT (estrogen alone or estrogen plus progesterone) results in higher incidence of dry eyes as compared to lower doses of HRT.[163]
In contrast, some studies have shown beneficial effects of HRT on dry eye signs and symptoms in post-menopausal women. HRT, in the form of oral and transdermal estrogen and estrogen plus progesterone therapy, reduces dry eye symptoms and have a positive impact on tear production, tear osmolarity and tear film stability.[147], [155], [164], [165], [166], [167], [168], [169], [170], [171], [172] Another study showed that topical application of estrogen eye drop and ointment has a beneficial role on tear function, thus improving dry eye symptoms. This shows that local estrogen therapy may be superior to systemic HT in improving dry eye symptoms as systemic HT can’t penetrate the blood- eye barrier, thus hindering its effect on the conjunctivae.[172], [173] Duration of HRT also affects the outcome, as one study showed that women taking HRT for > 5 years had less ocular symptoms and increased tear production as compared to women taking HRT for <5 years.[167] A significant relationship between HRT and dry eye is yet to be established and larger prospective-controlled studies with long follow-up time are required in this field to reach a definite conclusion.
Role of Androgen treatment in dry eye
Androgens have a crucial role in tear production and have a positive impact on function of meibomian and lacrimal gland.[174] Testosterone reduces symptom of dry eye in postmenopausal women[175], [176] and in Klinefelter’s syndrome patients[177] Patients with complete androgen insensitivity syndrome, men using androgen blockers and women having significantly low testosterone levels have higher chances of dry eye, this shows that androgen deficiency can lead to tear film instability and dysfunction.[50] These patients can be benefited by systemic androgen therapy but the undesirable side effects of systemic androgen therapy should also be considered when using in peri- and post-menopausal women. A study in postmenopausal women using Estratest therapy, a combination of methyltestosterone and estrogen, showsed improvement in dry eye symptoms.[178] A synthetic steroid hormone, Tibolone, which hase androgenic as well as estrogenic and progestogenic properties, was used in post-menopausal women with Sjogren’s syndrome to treat dry eye. After 3 and 12 months of treatment, it increased Schirmer’s test scores and decreased dry eye symptoms.[179] Use of androgen precursors like DHEA in Sjogren’s syndrome patients for 9 months showed no changes in dry eye symptoms.[180], [73] A study using depot testosterone in Sjogren’s syndrome patients showed significant improvement in ocular surface inflammation and tear production.[181] A recent study in women with low testosterone levels and evaporative dry eye treated with androgen patch showed improvement in Schirmer’s test scores and TBUT after 3 weeks of treatment.[182]
To prevent the side effects of systemic androgen therapy and to limit systemic absorption of androgen, local androgen treatment modalities like androgen eye drop and transdermal androgen cream has been developed. National Institute of Health found that significant number of dry eye patients become asymptomatic after using testosterone eye drop for 6 months.[183] Irritation is common with androgen eye drop due to poor solubility of androgen. To make it more soluble and less irritating, cyclodextrin, a solubilizing compound is used with androgen eye drop and this newer conjugated androgen eye drop yielded positive results in improving dry eye signs and symptoms.[174] Some studies also shows that application of testosterone cream to the eyelids significantly reduces dry eye symptoms and normalizes TBUT and lipid layer thickness of the tear film.[70], [184] These new local androgen treatment modalities are efficacious and more tolerable to the patient. Studies on dry eye and androgen therapy are limited but most study shows consistent positive relationship between androgen therapy and improvement in dry eye symptoms. Large population based clinical studies are required in this field to determine the benefit of using androgen therapy in dry eye disease.
Candidate selection and Prognosis for hormonal treatment of DED
Age and endogenous hormone levels are the most important factors which should be considered while selecting patients for hormonal treatment of DED.
HRT significantly improves tear production in patients < 50 years old than older patients >50 years and improvement in tear production and age of the patient are negatively correlated.[185] In early menopausal period, estrogen may be useful but in later life, systemic and ocular side effects are more common.[186] Androgen eye drops are more beneficial in peri- and post-menopausal women than pre-menopausal women.[184]
Patients with abnormally low endogenous testosterone levels like women with complete androgen insensitivity syndrome, men on androgen blockers and women with abnormally low testosterone levels are most benefitted from systemic and local androgen treatment and shows complete resolution of symptoms after using androgen therapy. [50], [187]
Summary
Presence of gonadal hormone receptors, mRNAs and proteins in the meibomian gland, lacrimal gland, conjunctiva and cornea depicts that these tissues are influenced by gonadal hormones. Specific influence on gene expression by gonadal hormones may be the cause of sex- related differences in the structural and functional characteristics of these tissues. Dry eye disease (DED) is a multifactorial immune-mediated inflammatory disease affecting the ocular tissues and gonadal hormones are known to produce effects on the immune system. DED mostly affects women and elderly population and post-menopausal women are more commonly affected. It can be due to low androgen levels in these population as androgen has anti-inflammatory role on the ocular surface. Effects of estrogen and progesterone in dry eye is unclear as dry eye is seen in both high and low estrogen states. It is believed that estrogen and progesterone act indirectly via inhibiting androgen actions on the ocular surface. Recent evidence suggests that imbalances in the levels of testosterone, estrogen and progesterone affects the lacrimal functional unit/OSS, promotes inflammatory processes in them and influences the pathophysiology of dry eye.
HRT therapy, including systemic estrogen or estrogen plus progesterone therapy, have conflicting results on dry eye symptoms, mostly showing no benefit or increasing the symptoms of dry eye. On the other hand, systemic or local androgen therapy shows consistent beneficial effects in dry eye disease. However, more large scale human studies are still needed in this field to determine the effects of gonadal hormones on ocular surface tissues and dry eye disease. It may be possible to develop new therapeutic strategies targeting the pathophysiology of DED through palliation of hormonal imbalances.
Source of Funding
None.
Conflicts of interest
There are no conflicts of interest.
References
- . The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Work Shop. Ocul Surf 2007. [Google Scholar]
- S McGinnigle, SA Naroo, F Eperjesi. Evaluation of Dry Eye. Surv Ophthalmol 2012. [Google Scholar] [Crossref]
- B Miljanović, R Dana, DA Sullivan, Debra A. Schaumberg. Impact of Dry Eye Syndrome on Vision-Related Quality of Life. Am J Ophthalmol 2007. [Google Scholar] [Crossref]
- M Uchino, DA Schaumberg. Dry Eye Disease: Impact on Quality of Life and Vision. Curr Ophthalmol Rep 2013. [Google Scholar] [Crossref]
- RP Maurya. Dry eye disease: An overview. Indian J Clin Exp Ophthalmol 2019. [Google Scholar]
- L Dorennavar, RP Maurya, VP Singh, MK Singh, K Sharma, R Sharma. The role of Rebamipide ophthalmic suspension in management of dry eye disease. Indian J Clin Exp Ophthalmol 2015. [Google Scholar] [Crossref]
- JA Smith. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop. Ocul Surf 2007. [Google Scholar]
- DA Schaumberg, R Dana, JE Buring, DA Sullivan. Prevalence of dry eye disease among US men: estimates from the Physicians’ Health Studies. Arch Ophthalmol 2009. [Google Scholar]
- DA Schaumberg, DA Sullivan, JE Buring, MR Dana. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003. [Google Scholar] [Crossref]
- DA Schaumberg, M Uchino, WG Christen, RD Semba, JE Buring, JZ Li. Patient Reported Differences in Dry Eye Disease between Men and Women: Impact, Management, and Patient Satisfaction. PLoS ONE 2013. [Google Scholar] [Crossref]
- DA Sullivan, KM Hammitt, DA Schaumberg, BD Sullivan, CG Begley, P Gjorstrup. Report of the TFOS/ARVO Symposium on Global Treatments for Dry Eye Disease: An Unmet Need. Ocul Surf 2012. [Google Scholar] [Crossref]
- D Dursun, D Monroy, R Knighton, T Tervo, M Vesaluoma, K Carraway. The effects of experimental tear film removal on corneal surface regularity and barrier function. Ophthalmology 2000. [Google Scholar] [Crossref]
- E Goto, Y Yagi, Y Matsumoto, K Tsubota. Impaired functional visual acuity of dry eye patients. Am J Ophthalmol 2002. [Google Scholar] [Crossref]
- MA Lemp. Report of the National Eye Institute/ Industry workshop on clinical trials in dry eyes. Eye Contact Lens 1995. [Google Scholar]
- P Rosenthal, D Borsook. The Corneal Pain System. Part I: The Missing Piece of the Dry Eye Puzzle. Ocular Surface 2012. [Google Scholar] [Crossref]
- IK Gipson. The Ocular Surface: The Challenge to Enable and Protect Vision. Invest Ophthalmol Vis Sci 2007. [Google Scholar] [Crossref]
- ME Stern, RW Beuerman, RI Fox, J Gao, AK Mircheff, SC Pflugfelder. The pathology of dry eye: The interaction between the ocular surface and lacrimal glands. Cornea 1998. [Google Scholar]
- ME Stern, RW Beuerman, RI Fox, J Gao, AK Mircheff, SC Pflugfelder. A unified theory of the role of the ocular surface in dry eye. Adv Exp Med Biol 1998. [Google Scholar]
- DQ Li, L Luo, Z Chen, HS Kim, XJ Song, SC Pflugfelder. JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res 2006. [Google Scholar]
- L Luo, DQ Li, A Doshi, W Farley, RM Corrales, SC Pflugfelder. Experimental Dry Eye Stimulates Production of Inflammatory Cytokines and MMP-9 and Activates MAPK Signaling Pathways on the Ocular Surface. Invest Ophthalmol Vis Sci 2004. [Google Scholar] [Crossref]
- S Barabino, M Dana. Dry eye syndromes. Chem Immunol Allergy 2007. [Google Scholar]
- SC Pflugfelder. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004. [Google Scholar] [Crossref]
- . Anti-inflammatory therapy for dry eye. Am J Ophthalmol 2004; 137: 337–342. 23.Research in dry eye: report of the Research Subcommittee of the International Dry Eye Work Shop (2007). Ocul Surf 2007. [Google Scholar]
- AJ Bron. Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye Work Shop. Ocul Surf 2007. [Google Scholar]
- WD Mathers, JA Lane. Meibomian gland lipids, evaporation, and tear film stability. Adv Exp Med Biol 1998. [Google Scholar]
- M Guillon, C Maissa. Tear film evaporation-effect of age and gender. Cont Lens Anterior Eye 2010. [Google Scholar]
- C Maissa, M Guillon. Tear film dynamics and lipid layer characteristics- effect of age and gender. Cont Lens Anterior Eye 2010. [Google Scholar]
- AJ Bron, JM Tiffany, SM Gouveia, N Yokoi, LW Voon. Functional aspects of the tear film lipid layer. Exp Eye Res 2004. [Google Scholar] [Crossref]
- AJ Bron, N Yokoi, E Gaffney, JM Tiffany. Predicted Phenotypes of Dry Eye: Proposed Consequences of Its Natural History. Ocular Surface 2009. [Google Scholar] [Crossref]
- E Knop, N Knop, T Millar, H Obata, DA Sullivan. The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Anatomy, Physiology, and Pathophysiology of the Meibomian Gland. Invest Ophthalmol Vis Sci 2011. [Google Scholar] [Crossref]
- MA Lemp, LA Crews, AJ Bron, GN Foulks, BD Sullivan. Distribution of Aqueous-Deficient and Evaporative Dry Eye in a Clinic-Based Patient Cohort. Cornea 2012. [Google Scholar] [Crossref]
- CA Blackie, DR Korb, E Knop, R Bedi, N Knop, EJ Holland. Nonobvious Obstructive Meibomian Gland Dysfunction. Cornea 2010. [Google Scholar] [Crossref]
- SG Min, MS Ha. Calculated CT volumes of lacrimal glands in normal Korean orbits. J Korean Opthalmol Soc 2015. [Google Scholar]
- AK Mircheff, Y Wang, C Ding, DW Warren, JE Schechter. Potentially Pathogenic Immune Cells and Networks in Apparently Healthy Lacrimal Glands. Ocular Surface 2015. [Google Scholar] [Crossref]
- RP Maurya, V Singh, A Gupta, VP Singh, A Kumar, A Yadav. Dry eye disease associated with Primary Sjogren syndrome: An update. Indian J Clin Exp Ophthalmol 2021. [Google Scholar] [Crossref]
- DA Sullivan, LA Wickham, EM Rocha, KL Krenzer, BD Sullivan, R Steagall. Androgens and Dry Eye in Sjogren's Syndromea. Ann N Y Acad Sci 1999. [Google Scholar] [Crossref]
- D A Sullivan, A Belanger, J M Cermak, R Berube, A S Papas, R M Sullivan. Are women with Sjögren’s syndrome androgen deficient?. J Rheumatol 2003. [Google Scholar]
- JM Cermak, KL Krenzer, RM Sullivan, MR Dana, DA Sullivan. Is Complete Androgen Insensitivity Syndrome Associated with Alterations in the Meibomian Gland and Ocular Surface?. Cornea 2003. [Google Scholar] [Crossref]
- BD Sullivan, JE Evans, JM Cermak, KL Krenzer, MR Dana, DA Sullivan. Complete androgen insensitivity syndrome: effect on human meibomian gland secretions. Arch Ophthalmol 2002. [Google Scholar]
- J A Smith, S Vitale, G F Reed, S A Grieshaber, L A Goodman, V H Vanderhoof. Dry eye signs and symptoms in women with premature ovarian failure. Arch Ophthalmol 2004. [Google Scholar]
- SC Pflugfelder. Hormonal Deficiencies and Dry Eye. Arch Ophthalmol 2004. [Google Scholar] [Crossref]
- G F Yavas, F Ozturk, T Kusbeci, S S Ermis, M Yilmazer, S Cevrioglu. Meibomian gland alterations in polycystic ovary syndrome. Curr Eye Res 2008. [Google Scholar]
- BD Sullivan, JE Evans, KL Krenzer, RM Dana, DA Sullivan. Impact of antiandrogen treatment on the fatty acid profile of neutral lipids in human meibomian gland secretions. J Clin Endocrinol Metab 2000. [Google Scholar]
- RP Maurya, VP Singh, S Chaudhary, M Roy, Tanmay Srivastav. Prevalence of severe dry eye disease in postmenopausal women in North India: A teaching hospital study. Indian J Obstet Gynecol Res 2019. [Google Scholar] [Crossref]
- KL Krenzer, MR Dana, MD Ullman, JM Cermak, DB Tolls, JE Evans. Effect of Androgen Deficiency on the Human Meibomian Gland and Ocular Surface1. J Clin Endocrinol Metab 2000. [Google Scholar] [Crossref]
- JP McCulley, WE Shine. The lipid layer of tears: dependent on meibomian gland function. Exp Eye Res 2004. [Google Scholar] [Crossref]
- DA Sullivan, EM Rocha, MD Ullman, KL Krenzer, J Gao, I Toda. Androgen regulation of the meibomian gland. Adv Exp Med Biol 1998. [Google Scholar]
- DA Sullivan, BD Sullivan, MD Ullman, EM Rocha, KL Krenzer, JM Cermak. Androgen influence on the meibomian gland. Invest Ophthalmol Vis Sci 2000. [Google Scholar]
- D A Sullivan, H Yamagami, M Liu, T Suzuki, K L Krenzer, J M Cermak. Sex steroids, the meibomian gland and evaporative dry eye. Cornea 2000. [Google Scholar] [Crossref]
- DA Sullivan, BD Sullivan, JE Evans, F Schirra, H Yamagami, M Liu. Androgen Deficiency, Meibomian Gland Dysfunction, and Evaporative Dry Eye. Ann N Y Acad Sci 2002. [Google Scholar] [Crossref]
- T Suzuki, F Schirra, SM Richards, RV Jensen, DA Sullivan. Estrogen and Progesterone Control of Gene Expression in the Mouse Meibomian Gland. Invest Ophthalmol Vis Sci 2008. [Google Scholar] [Crossref]
- D A Sullivan, R V Jensen, T Suzuki, S M Richards. Do sex steroids exert sex-specific and/or opposite effects on gene expression in lacrimal and meibomian glands?. Mol Vis 2009. [Google Scholar]
- E M Rocha, L A Wickham, L A Da Silveira. Identification of androgen receptor protein and 5alpha-reductase mRNA in human ocular tissues. Br J Ophthalmol 2000. [Google Scholar]
- H Yamagami, F Schirra, M Liu, SM Richards, BD Sullivan, DA Sullivan. Androgen influence on gene expression in the meibomian gland. Adv Exp Med Biol 2002. [Google Scholar]
- F Schirra, T Suzuki, DP Dickinson, DJ Townsend, IK Gipson, DA Sullivan. Identification of Steroidogenic Enzyme mRNAs in the Human Lacrimal Gland, Meibomian Gland, Cornea, and Conjunctiva. Cornea 2006. [Google Scholar] [Crossref]
- H Obata. Anatomy and histopathology of human meibomian gland. Cornea 2002. [Google Scholar]
- M Mrugacz, N Zywalewska, A Bakunowicz-Lazarczyk. Neuronal and hormonal regulatory mechanisms of tears production and secretion. Klin Oczna 2005. [Google Scholar]
- PJ Driver, MA Lemp. Meibomian gland dysfunction. Surv Ophthalmol 1996. [Google Scholar] [Crossref]
- B D Sullivan, J E Evans, M R Dana, D A Sullivan. Influence of aging on the polar and neutral lipid profiles in human meibomian gland secretions. Arch Ophthalmol 2006. [Google Scholar]
- BD Sullivan, JE Evans, MR Dana, DA Sullivan. Impact of androgen deficiency on the lipid profiles in human meibomian gland secretions. Adv Exp Med Biol 2002. [Google Scholar]
- F Labrie, A Belanger, J Simard, LT Van, C Labrie. DHEA and Peripheral Androgen and Estrogen Formation: Intracrinology. Ann N Y Acad Sci 1995. [Google Scholar] [Crossref]
- F Labrie, A Bélanger, L Cusan, JL Gomez, B Candas. Marked Decline in Serum Concentrations of Adrenal C19 Sex Steroid Precursors and Conjugated Androgen Metabolites During Aging. J Clin Endocrinol Metab 1997. [Google Scholar] [Crossref]
- M Guillon, C Maïssa. Tear film evaporation—Effect of age and gender. Cont Lens Anterior Eye 2010. [Google Scholar] [Crossref]
- F Labrie. DHEA, important source of sex steroids in men and even more in women. Prog Brain Res 2010. [Google Scholar]
- PG Hykin, AJ Bron. Age-Related Morphological Changes in Lid Margin and Meibomian Gland Anatomy. Cornea 1992. [Google Scholar] [Crossref]
- PE Pochi, JS Strauss, DT Downing. Age-related Changes in Sebaceous Gland Activity. J Invest Dermatol 1979. [Google Scholar] [Crossref]
- WD Mathers, JA Lane, MB Zimmerman. Tear Film Changes Associated with Normal Aging. Cornea 1996. [Google Scholar] [Crossref]
- J Shimazaki, M Sakata, K Tsubota. Ocular surface changes and discomfort in patients with meibomian gland dysfunction. Arch Ophthalmol 1995. [Google Scholar]
- M Norn. Expressibility of meibomian secretion. Relation to age, lipid precorneal film, scales, foam, hair and pigmentation. Acta Ophthalmol 1987. [Google Scholar]
- C Worda, J Nepp, JC Huber, MO Sator. Treatment of keratoconjunctivitis sicca with topical androgen. Maturitas 2001. [Google Scholar] [Crossref]
- RM Schiffman, R Bradford, B Bunnell, F Lai, P Bernstein, SW Whitcup. A multi-center, double-masked, randomized, vehicle-controlled, parallel group study to evaluate the safety and efficacy of testosterone ophthalmic solution in patients with meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2006. [Google Scholar]
- MA Zeligs, K Gordon. Dehydroepiandrosterone therapy for the treatment of eye disorders. (International Patent) International Publication Number: WO 94/04155. 1994. [Google Scholar]
- SR Pillemer, MT Brennan, V Sankar, RA Leakan, JA Smith, M Grisius. Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome. Arthritis Care Res 2004. [Google Scholar] [Crossref]
- A Hartkamp, R Geenen, GLR Godaert, H Bootsma, AA Kruize, JWJ Bijlsma. Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren syndrome: a randomised controlled trial. Ann Rheum Dis 2008. [Google Scholar] [Crossref]
- Y T Konttinen, V Stegajev, A Al-Samadi, P Porola, J Hietanen, M Ainola. Sjogren’s syndome and extragonadal sex steroid formation: a clue to a better disease control?. J Steroid Biochem Mol Biol 2015. [Google Scholar]
- L. Azzi, M El-Alfy, F Labrie. Gender differences and effects of sex steroids and dehydroepiandrosterone on androgen and oestrogen α receptors in mouse sebaceous glands. Br J Dermatol 2006. [Google Scholar] [Crossref]
- G Sansone-Bazzano, RM Reisner, G Bazzano. A Possible Mechanism of Action of Estrogen at the Cellular Level in a Model Sebaceous Gland. J Invest Dermatol 1972. [Google Scholar] [Crossref]
- SM Richards, H Yamagami, F Schirra, T Suzuki, DA Sullivan, RV Jensen. Sex-Related Effect on Gene Expression in the Mouse Meibomian Gland. Curr Eye Res 2006. [Google Scholar] [Crossref]
- RR Darabad, T Suzuki, SM Richards, RV Jensen, FA Jakobiec, FR Zakka. Influence of Aromatase Absence on the Gene Expression and Histology of the Mouse Meibomian Gland. Invest Ophthalmol Vis Sci 2013. [Google Scholar] [Crossref]
- H Yamagami, SM Richards, BD Sullivan, M Liu, RJ Steagall, DA Sullivan. Gender-associated differences in gene expression of the meibomian gland. Adv Exp Med Biol 2002. [Google Scholar]
- H Yamagami, F Schirra, M Liu, SM Richards, BD Sullivan, DA Sullivan. Androgen influence on gene expression in the meibomian gland. Adv Exp Med Biol 2002. [Google Scholar]
- DA Dartt. Signal transduction and control of lacrimal gland protein secretion: A review. Curr Eye Res 1989. [Google Scholar] [Crossref]
- JL Ubels, IK Gipson, SJ Spurr-Michaud, AS Tisdale, RE Van Dyken, MP Hatton. Gene Expression in Human Accessory Lacrimal Glands of Wolfring. Invest Ophthalmol Vis Sci 2012. [Google Scholar] [Crossref]
- DA Sullivan, JA Edwards, LA Wickham, JDO Pena, J Gao, M Ono. Identification and endocrine control of sex steroid binding sites in the lacrimal gland. Curr Eye Res 1996. [Google Scholar] [Crossref]
- SM Richards, M Liu, RV Jensen, F Schirra, H Yamagami, MJ Lombardi. Androgen regulation of gene expression in the mouse lacrimal gland. J Steroid Biochem Mol Biol 2005. [Google Scholar] [Crossref]
- T Suzuki, F Schirra, SM Richards, NS Treister, MJ Lombardi, P Rowley. Estrogen’s and Progesterone’s Impact on Gene Expression in the Mouse Lacrimal Gland. Invest Ophthalmol Vis Sci 2006. [Google Scholar] [Crossref]
- DA Sullivan, L Block, JDO Pena. Influence of androgens and pituitary hormones on the structural profile and secretory activity of the lacrimal gland. Acta Ophthalmol Scand 1996. [Google Scholar]
- AM Azzarolo, AK Mircheff, RL Kaswan, FZ Stanczyk, E Gentschein, L Becker. Androgen support of lacrimal gland function. Endocrine 1997. [Google Scholar] [Crossref]
- J Pfeilschifter, R Köditz, M Pfohl, H Schatz. Changes in Proinflammatory Cytokine Activity after Menopause. Endocrine Rev 2002. [Google Scholar] [Crossref]
- N Ishimaru, K Saegusa, K Yanagi, N Haneji, I Saito, Y Hayashi. Estrogen Deficiency Accelerates Autoimmune Exocrinopathy in Murine Sjögren's Syndrome through Fas-Mediated Apoptosis. Am J Pathol 1999. [Google Scholar] [Crossref]
- DA Sullivan, LA Wickham, EM Rocha, RS Kelleher, LA Da Silveira, I Toda. Influence of gender, sex steroid hormones, and the hypothalamic-pituitary axis on the structure and function of the lacrimal gland. Adv Exp Med Biol 1998. [Google Scholar]
- DA Sullivan, KJ Bloch, MR Allansmith. Hormonal influence on the secretory immune system of the eye: androgen control of secretory component production by the rat exorbital gland. Immunology 1984. [Google Scholar]
- DA Sullivan, MR Allansmith. Hormonal influence on the secretory immune system of the eye: androgen modulation of IgA levels in tears of rats. J Immunol 1985. [Google Scholar]
- DA Sullivan. Influence of the hypothalamic-pituitary axis on the androgen regulation of the ocular secretory immune system. J Steroid Biochem 1988. [Google Scholar]
- DA Sullivan, KJ Bloch, MR Allansmith. Hormonal influence on the secretory immune system of the eye: androgen regulation of secretory component levels in rat tears. J Immunol 1984. [Google Scholar]
- AM Azzarolo, AH Mazaheri, AK Mircheff, DW Warren. Sex-dependent parameters related to electrolyte, water and glycoprotein secretion in rabbit lacrimal glands. Curr Eye Res 1993. [Google Scholar] [Crossref]
- DA Sullivan, MR Allansmith. Hormonal modulation of tear volume in the rat. Exp Eye Res 1986. [Google Scholar] [Crossref]
- WD Mathers, D Stovall, JA Lane, MB Zimmerman, S Johnson. Menopause and tear function: the influence of prolactin and sex hormones on human tear production. Cornea 1998. [Google Scholar]
- P Versura, EC Campos. Menopause and dry eye. A possible relationship. Gynecological Endocrinol 2005. [Google Scholar] [Crossref]
- SP Chen, G Massaro-Giordano, M Pistilli, CA Schreiber, VY Bunya. Tear Osmolarity and Dry Eye Symptoms in Women Using Oral Contraception and Contact Lenses. Cornea 2013. [Google Scholar] [Crossref]
- DA Sullivan, KL Krenzer, BD Sullivan, DB Tolls, I Toda, MR Dana. Does androgen insufficiency cause lacrimal gland inflammation and aqueous tear deficiency?. Invest Ophthalmol Vis Sci 1999. [Google Scholar]
- FJ Rocha, LA Wickham, JDO Pena, J Gao, M Ono, RW Lambert. Influence of gender and the endocrine environment on the distribution of androgen receptors in the lacrimal gland. J Steroid Biochem Mol Biol 1993. [Google Scholar] [Crossref]
- SM Richards, RV Jensen, M Liu, BD Sullivan, MJ Lombardi, P Rowley. Influence of sex on gene expression in the mouse lacrimal gland. Exp Eye Res 2006. [Google Scholar] [Crossref]
- I Toda, LA Wickham, DA Sullivan. Gender and Androgen Treatment Influence the Expression of Proto-oncogenes and Apoptotic Factors in Lacrimal and Salivary Tissues of MRL/lprMice. Clin Immunol Immunopathol 1998. [Google Scholar] [Crossref]
- J Gao, RW Lambert, LA Wickham, G Banting, DA Sullivan. Androgen control of secretory component mRNA levels in the rat lacrimal gland. J Steroid Biochem Mol Biol 1995. [Google Scholar] [Crossref]
- J Winderickx, I Vercaeren, G Verhoeven, W Heyns. Androgen-dependent expression of cystatin-related protein (CRP) in the exorbital lacrimal gland of the rat. J Steroid Biochem Mol Biol 1994. [Google Scholar] [Crossref]
- I Toda, BD Sullivan, LA Wickham, DA Sullivan. Gender- and androgen-related influence on the expression of proto-oncogene and apoptotic factor mRNAS in lacrimal glands of autoimmune and non-autoimmune mice. J Steroid Biochem Mol Biol 1999. [Google Scholar] [Crossref]
- M Ono, FJ Rocha, DA Sullivan. Immunocytochemical location and hormonal control of androgen receptors in lacrimal tissues of the female MRL/Mp-Ipr/Ipr mouse model of sjögren's syndrome. Exp Eye Res 1995. [Google Scholar] [Crossref]
- RW Lambert, RS Kelleher, LA Wickham, JP Vaerman, DA Sullivan. Neuroendocrinimmune modulation of secretory component production by rat lacrimal, salivary, and intestinal epithelial cells. Invest Ophthalmol Vis Sci 1994. [Google Scholar]
- JL Ubels, JT Wertz, KE Ingersoll, RS Jackson II, MD Aupperlee. Down-regulation of Androgen Receptor Expression and Inhibition of Lacrimal Gland Cell Proliferation by Retinoic Acid. Exp Eye Res 2002. [Google Scholar] [Crossref]
- EH Sato, DA Sullivan. Comparative influence of steroid hormones and immunosuppressive agents on autoimmune expression in lacrimal glands of a female mouse model of Sjögren’s syndrome. Invest Ophthalmol Vis Sci 1994. [Google Scholar]
- S Mostafa, V Seamon, AM Azzarolo. Influence of sex hormones and genetic predisposition in Sjögren’s syndrome: A new clue to the immunopathogenesis of dry eye disease. Exp Eye Res 2012. [Google Scholar] [Crossref]
- DA Sullivan, MR Allansmith. Hormonal influence on the secretory immune system of the eye: endocrine interactions in the control of IgA and secretory component levels in tears of rats. Immunology 1987. [Google Scholar]
- AH Cornell-Bell, DA Sullivan, MR Allansmith. Gender-related differences in the morphology of the lacrimal gland. Invest Ophthalmol Vis Sci 1985. [Google Scholar]
- D Sullivan, R Kelleher, J Vaerman, L Hann. Androgen regulation of secretory component synthesis by lacrimal gland acinar cells in vitro. J Immunol 1990. [Google Scholar]
- H Vanaken, F Claessens, I Vercaeren, W Heyns, B Peeters, W Rombauts. Androgenic induction of cystatin-related protein and the C3 component of prostatic binding protein in primary cultures from the rat lacrimal gland. Mol Cell Endocrinol 1996. [Google Scholar] [Crossref]
- S Singh, L Moksha, N Sharma, JS Titiyal, NR Biswas, T Velpandian. Development and evaluation of animal models for sex steroid deficient dry eye. J Pharmacol Toxicol Methods 2014. [Google Scholar] [Crossref]
- X Song, P Zhao, G Wang, X Zhao. The effects of estrogen and androgen on tear secretion and matrix metalloproteinase-2 expression in lacrimal glands of ovariectomized rats. Invest Ophthalmol Vis Sci 2014. [Google Scholar]
- D Vavilis, S Maloutas, M Nasioutziki, E Boni, J Bontis. Conjunctiva is an estrogen-sensitive epithelium. Acta Obstet Gynecol Scand 1995. [Google Scholar] [Crossref]
- C Zylberberg, V Seamon, O Ponomareva, K Vellala, M Deighan, AM Azzarolo. Estrogen up-regulation of metalloproteinase-2 and -9 expression in rabbit lacrimal glands. Exp Eye Res 2007. [Google Scholar] [Crossref]
- S Srinivasan, E Joyce, M Senchyna, T Simpson, L Jones. Clinical signs and symptoms in post-menopausal females with symptoms of dry eye. Ophthalmic Physiol Opt 2008. [Google Scholar] [Crossref]
- H Obata, S Yamamoto, H Horiuchi, R Machinami. Histopathologic study of human lacrimal gland. Statistical analysis with special reference to aging. Ophthalmology 1995. [Google Scholar]
- AM Azzarolo, H Eihausen, J Schechter. Estrogen prevention of lacrimal gland cell death and lymphocytic infiltration. Exp Eye Res 2003. [Google Scholar] [Crossref]
- WS Alexander, DJ Hilton. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 2004. [Google Scholar]
- RR Darabad, T Suzuki, SM Richards, FA Jakobiec, FR Zakka, S Barabino. Does estrogen deficiency cause lacrimal gland inflammation and aqueous-deficient dry eye in mice?. Exp Eye Res 2014. [Google Scholar] [Crossref]
- IK Gipson. Distribution of mucins at the ocular surface. Exp Eye Res 2004. [Google Scholar] [Crossref]
- IK Gipson, P Argüeso. Role of mucins in the function of the corneal and conjunctival epithelia. Int Rev Cytol Salt Lake City 2003. [Google Scholar]
- TJ Millar, ST Tragoulias, PJ Anderton, MS Ball, F Miano, GR Dennis. The Surface Activity of Purified Ocular Mucin at the Air-Liquid Interface and Interactions With Meibomian Lipids. Cornea 2006. [Google Scholar] [Crossref]
- L Rivas, MA Oroza, A Perez-Esteban, J Murube-del-Castillo. Morphological changes in ocular surface in dry eyes and other disorders by impression cytology. Graefes Arch Clin Exp Ophthalmol 1992. [Google Scholar] [Crossref]
- RA Ralph. Conjunctival goblet cell density in normal subjects and in dry eye syndromes. Invest Ophthalmol Vis Sci 1975. [Google Scholar]
- JD Nelson, JC Wright. Conjunctival Goblet Cell Densities in Ocular Surface Disease. Arch Ophthalmol 1984. [Google Scholar] [Crossref]
- P Argueso, M Balaram, S Spurr-Michaud, HT Keutmann, MR Dana, IK Gipson. Decreased levels of the goblet cell mucinMUC5ACin tears of patients with Sjögren syndrome. Invest Ophthalmol Vis Sci 2002. [Google Scholar]
- Y Danjo, H Watanabe, A S Tisdale, M George, T Tsumura, M B Abelson. Alteration of mucin in human conjunctival epithelia in dry eye. Invest Ophthalmol Vis Sci 1998. [Google Scholar]
- JD Nelson, VR Havener, JD Cameron. Cellulose acetate impressions of the ocular surface. Dry eye states. Arch Ophthalmol 1983. [Google Scholar]
- S Bonini, F Mantelli, C Moretti, A Lambiase, S Bonini, A Micera. Itchy-Dry Eye Associated with Polycystic Ovary Syndrome. Am J Ophthalmol 2007. [Google Scholar] [Crossref]
- F Mantelli, C Moretti, A Micera, S Bonini. Conjunctival mucin deficiency in complete androgen insensitivity syndrome (CAIS). Graefes Arch Clin Exp Ophthalmol 2007. [Google Scholar] [Crossref]
- P Versura, M Fresina, EC Campos. Ocular surface changes over the menstrual cycle in women with and without dry eye. Gynecol Endocrinol 2007. [Google Scholar] [Crossref]
- AM Serrander, KE Peek. Changes in contact lens comfort related to the menstrual cycle and menopause. A review of articles. J Am Optom Assoc 1993. [Google Scholar]
- F Feldman, J Bain, AR Matuk. Daily Assessment of Ocular and Hormonal Variables Throughout the Menstrual Cycle. Arch Ophthalmol 1978. [Google Scholar] [Crossref]
- P Kramer, V Lubkin, W Potter, M Jacobs, G Labay, P Silverman. Cyclic Changes in Conjunctival Smears from Menstruating Females. Ophthalmology 1990. [Google Scholar] [Crossref]
- T Inatomi, S Spurr-Michaud, A S Tisdale, Q Zhan, S T Feldman, I K Gipson. Expression of secretory mucin genes by human conjunctival epithelia. Invest Ophthalmol Vis Sci 1996. [Google Scholar]
- C Lange, J Fernandez, D Shim, S Spurr-Michaud, A Tisdale, IK Gipson. Mucin gene expression is not regulated by estrogen and/or progesterone in the ocular surface epithelia of mice. Exp Eye Res 2003. [Google Scholar] [Crossref]
- T Inatomi, S Spurr-Michaud, A S Tisdale, I K Gipson. Human corneal and conjunctival epithelia express MUC1 mucin. Invest Ophthalmol Vis Sci 1995. [Google Scholar]
- IK Gipson, Y Hori, P Argüeso. Character of Ocular Surface Mucins and Their Alteration in Dry Eye Disease. Ocular Surface 2004. [Google Scholar] [Crossref]
- S Mitchell, P Abel, S Madaan, J Jeffs, K Chaudhary, G Stamp. Androgen-Dependent Regulation of Human MUC1 Mucin Expression. Neoplasia 2002. [Google Scholar] [Crossref]
- M Millodot. The influence of pregnancy on the sensitivity of the cornea.. Br J Ophthalmol 1977. [Google Scholar] [Crossref]
- P Affinito, AD Spiezio Sardo, CD Carlo, A Sammartino, GA Tommaselli, G Bifulco. Effects of hormone replacement therapy on ocular function in postmenopause. Menopause 2003. [Google Scholar] [Crossref]
- PM Kiely, LG Carney, G Smith. Menstrual Cycle Variations of Corneal Topography and Thickness. Am J Optom Physiol Opt 1983. [Google Scholar] [Crossref]
- B Riss, S Binder, P Riss, P Kemeter. Corneal sensitivity during the menstrual cycle.. Br J Ophthalmol 1982. [Google Scholar] [Crossref]
- NM Guttridge. Changes in ocular and visual variables during the menstrual cycle. Ophthalmic Physiol Opt 1994. [Google Scholar] [Crossref]
- PS Soni. Effects of Oral Contraceptive Steroids on the Thickness of Human Cornea. Am J Optom Physiol Opt 1980. [Google Scholar] [Crossref]
- M Millodot, A Lamont. Influence of menstruation on corneal sensitivity.. Br J Ophthalmol 1974. [Google Scholar] [Crossref]
- MM Ward, SC Stone, CA Sandman. Visual perception in women during the menstrual cycle. Physiol Behav 1978. [Google Scholar] [Crossref]
- D Vavilis, S Maloutas, M Nasioutziki, E Boni, J Bontis. Conjunctiva is an estrogen-sensitive epithelium. Acta Obstet Gynecol Scand 1995. [Google Scholar] [Crossref]
- A Pelit, T Bağiş, F Kayaselçuk, D Dursun, Y Akova, P Aydin. Tear Function Tests and Conjunctival Impression Cytology before and after Hormone Replacement Therapy in Postmenopausal Women. Eur J Ophthalmol 2003. [Google Scholar] [Crossref]
- D Vavilis, T Agorastos, M Vakiani, J Jafetas, D Panidis, T Konstantinidis. The effect of transdermal estradiol on the conjunctiva in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 1997. [Google Scholar] [Crossref]
- A Tomlinson. Effect of oral contraceptives on tear physiology. Ophthalmic Physiol Opt 2001. [Google Scholar] [Crossref]
- T Suzuki, DA Sullivan. Estrogen Stimulation of Proinflammatory Cytokine and Matrix Metalloproteinase Gene Expression in Human Corneal Epithelial Cells. Cornea 2005. [Google Scholar] [Crossref]
- P Aragona, D Puzzolo, A Micali, G Ferreri, D Britti. Morphological and Morphometric Analysis on the Rabbit Conjunctival Goblet Cells in Different Hormonal Conditions. Exp Eye Res 1998. [Google Scholar] [Crossref]
- MS Milner, KA Beckman, JI Luchs, QB Allen, RM Awdeh, J Berdahl. Dysfunctional tear syndrome: Dry eye disease and associated tear film disorders - New strategies for diagnosis and treatment. Curr Opin Ophthalmol 2017. [Google Scholar]
- DA Schaumberg, JE Buring, DA Sullivan, MR Dana. Hormone replacement therapy and dry eye syndrome.. JAMA 2001. [Google Scholar]
- B Shaharuddin, S Ismail-Mokhtar, Hussein E. Dry eye in post-menopausal Asian women on hormone replacement therapy. Int J Ophthalmol 2008. [Google Scholar]
- A AlAwlaqi, M Hammadeh. Examining the relationship between hormone therapy and dry-eye syndrome in postmenopausal women. Menopause 2016. [Google Scholar] [Crossref]
- H Coksuer, F Ozcura, F Oghan, B Haliloglu, C Coksuer. Effects of estradiol–drospirenone on ocular and nasal functions in postmenopausal women. Climacteric 2011. [Google Scholar] [Crossref]
- V Evans, T J Miller, J A Eden, MDP Willcox. Menopause, hormone replacement therapy and tear function. Adv Exp Med Biol 2002. [Google Scholar]
- JH Moon, JW Jung, KH Shin, HJ Paik. Effect of hormone replacement therapy on dry eye syndrome in postmenopausal women: a prospective study. J Korean Ophthalmol Soc 2010. [Google Scholar]
- AA Jensen, EJ Higginbotham, GM Guzinski, IL Davis, NJ Ellish. A survey of ocular complaints in postmenopausal women. J Assoc Acad Minor Phys 2000. [Google Scholar]
- Ö Altintaş, Y Caglar, N Yüksel, A Demirci, L Karabaş. The Effects of Menopause and Hormone Replacement Therapy on Quality and Quantity of Tear, Intraocular Pressure and Ocular Blood Flow. Ophthalmologica 2004. [Google Scholar] [Crossref]
- S Guaschino, E Grimaldi, A Sartore, R Mugittu, F Mangino, P Bortoli. Visual function in menopause: the role of hormone replacement therapy. Menopause 2003. [Google Scholar]
- A Okon´, P Jurowski, R Gos´. The influence of the hormonal replacement therapy on the amount and stability of the tear film among peri- and postmenopausal women. Klin Oczna 2001. [Google Scholar]
- M Metka, H Enzelsberger, W Knogler, B Schurz, H Aichmair. Eye manifestations as climacteric symptom. Geburtshilfe Frauenheilkd 1991. [Google Scholar]
- Michael O. Sator, Elmar A. Joura, Thomas Golaszewski, Doris Gruber, Peter Frigo, Markus Metka, Anton Hommer, Johannes C. Huber. Treatment of menopausal keratoconjunctivitis sicca with topical oestradiol. BJOG: An International Journal of Obstetrics and Gynaecology 1998. [Google Scholar] [Crossref]
- J Akramian, A Wedrich, J Nepp, M Sator. Estrogen therapy in keratoconjunctivitis sicca. Adv Exp Med Biol 1998. [Google Scholar]
- T Dawson. Testosterone eye drops: A novel treatment for dry eye disease. Ophthalmology Times 2015. [Google Scholar]
- M Appelmans. La ke´rato-conjonctivite se`che de Gougerot-Sjo¨gren. Arch Ophtalmol (Paris) 1948. [Google Scholar]
- R Bruckner. Uber einem erfolgreich mit perandren behandelten fall von Sjogren’schem symptomen complex. Ophthalmologica 1945. [Google Scholar]
- A Bizzarro, G Valentini, G Di Martino, A DaPonte, A De Bellis, G Iacono. Influence of Testosterone Therapy on Clinical and Immunological Features of Autoimmune Diseases Associated with Klinefelter’s Syndrome. J Clin Endocrinol Metab 1987. [Google Scholar] [Crossref]
- G Scott, SC Yiu, D Wasilewski, J Song, RE Smith. Combined Esterified Estrogen and Methyltestosterone Treatment for Dry Eye Syndrome in Postmenopausal Women. Am J Ophthalmol 2005. [Google Scholar] [Crossref]
- A Sartore, E Grimaldi, S Guaschino. The treatment of Sjögren's syndrome with tibolone: a case report. Am J Obstet Gynecol 2003. [Google Scholar] [Crossref]
- H Forsblad-d'Elia, H Carlsten, F Labrie, YT Konttinen, C Ohlsson. Low Serum Levels of Sex Steroids Are Associated with Disease Characteristics in Primary Sjogren’s Syndrome; Supplementation with Dehydroepiandrosterone Restores the Concentrations. J Clin Endocrinol Metab 2009. [Google Scholar] [Crossref]
- JM Akudugu, JP Slabbert, A Serafin, L Bohm. Frequency of Radiation-Induced Micronuclei in Neuronal Cells Does Not Correlate with Clonogenic Survival. Radiat Res 2000. [Google Scholar] [Crossref]
- MA Nanavaty, M Long, R Malhotra. Transdermal androgen patches in evaporative dry eye syndrome with androgen deficiency: a pilot study. Br J Ophthalmol 2014. [Google Scholar] [Crossref]
- A Plc. Safety and efficacy study of a testosterone eye drop for the treatment of meibomian gland dysfunction. Clinical trials, National Institute of Health; 2012. Available from: https://clinicaltrials.gov/ct2/show/NCT00755183. Last accessed on 2017 Jun 13].. . [Google Scholar]
- CG Conner. Symptomatic relief of dry eye assessed with the OSDI in patients using 5% testosterone cream. Invest Ophthalmol Vis Sci 2005. [Google Scholar]
- Y Feng, G Feng, S Peng, H Li. The effects of hormone replacement therapy on dry eye syndromes evaluated by Schirmer test depend on patient age. Cont Lens Anterior Eye 2016. [Google Scholar]
- B B Sherwin. Estrogen and cognitive aging in women. Neurosci 2006. [Google Scholar]
- J Dach. Bioidentical Hormones and Natural Thyroid [Last accessed on 2017 Jun 13].. 2014. [Google Scholar]
- Introduction
- Pathophysiology of Dry eye Disease
- Effects of gonadal hormones on Dry Eye -
- Gonadal hormones and the Meibomian gland
- Effects of androgen on the meibomian gland
- Effects of estrogen and progesterone on the meibomian gland
- Gonadal hormones and the lacrimal gland
- Gonadal hormones and the ocular surface
- Hormonal treatment in Dry eye
- Role of HRT in dry eye
- Role of Androgen treatment in dry eye
- Candidate selection and Prognosis for hormonal treatment of DED
- Summary
- Source of Funding
- Conflicts of interest